Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

著者: Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel Borràs, Jannes Govaerts, Stefan Naulaerts, Zwi Berneman, Benoit Beuselinck, Kalijn F. Bol, Jannie Borst, An Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V. Sorg, Radek Špíšek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I. Jolanda M. de Vries, Yanling Xiao, Abhishek D. Garg - OncoImmunology 2022 被引用: 124

T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.